Cipla submits application with USFDA for generic version of asthma drug

Drug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, which is used in the treatment of asthma and other respiratory disorders

Press Trust of India May 18, 2020 12:46:48 IST
Cipla submits application with USFDA for generic version of asthma drug

New Delhi: Drug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, which is used in the treatment of asthma and other respiratory disorders.

The company has submitted an abbreviated new drug application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the US Food and Drug Administration (USFDA), Cipla said in a regulatory filing.

The drug firm had recently announced the successful completion of its phase-3 clinical end-point study for the product in the first attempt, it added.

The product is indicated as a twice-daily prescription medicine to treat asthma in patients aged four years and older.

It is also used in the long term to treat chronic obstructive pulmonary disease (COPD), including chronic bronchitis, emphysema, or both, for better breathing.

According to IQVIA (IMS Health), Advair Diskus and its generic equivalents had US sales of around $2.9 billion for the 12-month period ending March 2020.

Cipla MD and Global CEO Umang Vohra said, “This marks a significant milestone and represents our commitment to increase patient access to complex treatment options in the respiratory space and will also play a major role in our strategy towards building a respiratory franchise in the US."

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Cipla's remdevisir to cost Rs 4,000 per 100 mg vial in India; pricing among lowest globally: Report
science

Cipla's remdevisir to cost Rs 4,000 per 100 mg vial in India; pricing among lowest globally: Report

Cipla India business chief executive officer Nikhil Chopra said that the company was launching Cipremi commercially on Wednesday and aims to supply over 80,000 vials within the first month, but did not give details on pricing.

Mylan's remdesivir to cost Rs 4,800 per 100 mg vial in India, 80% cheaper than price tag in wealthy nations
Health

Mylan's remdesivir to cost Rs 4,800 per 100 mg vial in India, 80% cheaper than price tag in wealthy nations

Gilead priced remdesivir at $2,340 per patient for rich nations and agreed to send nearly all of its supply of the drug to the United States over the next three months